![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The agreement aims to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg), approved for high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ferring Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 18, 2024